• Je něco špatně v tomto záznamu ?

Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX

J. Dvořanová, M. Kugler, J. Holub, V. Šícha, V. Das, J. Nekvinda, S. El Anwar, M. Havránek, K. Pospíšilová, M. Fábry, V. Král, M. Medvedíková, S. Matějková, B. Lišková, S. Gurská, P. Džubák, J. Brynda, M. Hajdúch, B. Grüner, P. Řezáčová

. 2020 ; 200 (-) : 112460. [pub] 20200518

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012260

Carbonic anhydrase IX (CA IX) is a transmembrane enzyme overexpressed in hypoxic tumors, where it plays an important role in tumor progression. Specific CA IX inhibitors potentially could serve as anti-cancer drugs. We designed a series of sulfonamide inhibitors containing carborane clusters based on prior structural knowledge of carborane binding into the enzyme active site. Two types of carborane clusters, 12-vertex dicarba-closo-dodecaborane and 11-vertex 7,8-dicarba-nido-undecaborate (dicarbollide), were connected to a sulfonamide moiety via aliphatic linkers of varying lengths (1-4 carbon atoms; n = 1-4). In vitro testing of CA inhibitory potencies revealed that the optimal linker length for selective inhibition of CA IX was n = 3. A 1-sulfamidopropyl-1,2-dicarba-closo-dodecaborane (3) emerged as the strongest CA IX inhibitor from this series, with a Ki value of 0.5 nM and roughly 1230-fold selectivity towards CA IX over CA II. X-ray studies of 3 yielded structural insights into their binding modes within the CA IX active site. Compound 3 exhibited moderate cytotoxicity against cancer cell lines and primary cell lines in 2D cultures. Cytotoxicity towards multicellular spheroids was also observed. Moreover, 3 significantly lowered the amount of CA IX on the cell surface both in 2D cultures and spheroids and facilitated penetration of doxorubicin. Although 3 had only a moderate effect on tumor size in mice, we observed favorable ADME properties and pharmacokinetics in mice, and preferential presence in brain over serum.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012260
003      
CZ-PrNML
005      
20211209131411.0
007      
ta
008      
210420s2020 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2020.112460 $2 doi
035    __
$a (PubMed)32505851
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Dvořanová, Jana $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900, Olomouc, Czech Republic
245    10
$a Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX / $c J. Dvořanová, M. Kugler, J. Holub, V. Šícha, V. Das, J. Nekvinda, S. El Anwar, M. Havránek, K. Pospíšilová, M. Fábry, V. Král, M. Medvedíková, S. Matějková, B. Lišková, S. Gurská, P. Džubák, J. Brynda, M. Hajdúch, B. Grüner, P. Řezáčová
520    9_
$a Carbonic anhydrase IX (CA IX) is a transmembrane enzyme overexpressed in hypoxic tumors, where it plays an important role in tumor progression. Specific CA IX inhibitors potentially could serve as anti-cancer drugs. We designed a series of sulfonamide inhibitors containing carborane clusters based on prior structural knowledge of carborane binding into the enzyme active site. Two types of carborane clusters, 12-vertex dicarba-closo-dodecaborane and 11-vertex 7,8-dicarba-nido-undecaborate (dicarbollide), were connected to a sulfonamide moiety via aliphatic linkers of varying lengths (1-4 carbon atoms; n = 1-4). In vitro testing of CA inhibitory potencies revealed that the optimal linker length for selective inhibition of CA IX was n = 3. A 1-sulfamidopropyl-1,2-dicarba-closo-dodecaborane (3) emerged as the strongest CA IX inhibitor from this series, with a Ki value of 0.5 nM and roughly 1230-fold selectivity towards CA IX over CA II. X-ray studies of 3 yielded structural insights into their binding modes within the CA IX active site. Compound 3 exhibited moderate cytotoxicity against cancer cell lines and primary cell lines in 2D cultures. Cytotoxicity towards multicellular spheroids was also observed. Moreover, 3 significantly lowered the amount of CA IX on the cell surface both in 2D cultures and spheroids and facilitated penetration of doxorubicin. Although 3 had only a moderate effect on tumor size in mice, we observed favorable ADME properties and pharmacokinetics in mice, and preferential presence in brain over serum.
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny nádorové $x metabolismus $7 D000951
650    _2
$a antitumorózní látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $7 D001943
650    _2
$a karboanhydrasa IX $x antagonisté a inhibitory $x metabolismus $7 D000071231
650    _2
$a inhibitory karboanhydras $x chemická syntéza $x chemie $x farmakologie $7 D002257
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a kultivované buňky $7 D002478
650    _2
$a psi $7 D004285
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a léky antitumorózní - screeningové testy $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši SCID $7 D016513
650    _2
$a molekulární struktura $7 D015394
650    _2
$a experimentální nádory $x farmakoterapie $x metabolismus $7 D009374
650    _2
$a rekombinantní proteiny $x metabolismus $7 D011994
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a sulfonamidy $x chemická syntéza $x chemie $x farmakologie $7 D013449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kugler, Michael $u Institute of Molecular Genetics of the Czech Academy of Sciences, Videňská 1083, 142 20, Prague 4, Czech Republic; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610, Prague 6, Czech Republic
700    1_
$a Holub, Josef $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, 250 68, Řež, Czech Republic
700    1_
$a Šícha, Václav $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, 250 68, Řež, Czech Republic
700    1_
$a Das, Viswanath $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900, Olomouc, Czech Republic
700    1_
$a Nekvinda, Jan $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, 250 68, Řež, Czech Republic; Department of Organic Chemistry, Faculty of Natural Science, Charles University, Hlavova 2030, 12800, Prague 2, Czech Republic
700    1_
$a El Anwar, Suzan $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, 250 68, Řež, Czech Republic
700    1_
$a Havránek, Miroslav $u Apigenex, s.r.o, Poděbradská 59/ 186, 180 66, Prague 9, Czech Republic
700    1_
$a Pospíšilová, Klára $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610, Prague 6, Czech Republic
700    1_
$a Fábry, Milan $u Institute of Molecular Genetics of the Czech Academy of Sciences, Videňská 1083, 142 20, Prague 4, Czech Republic
700    1_
$a Král, Vlastimil $u Institute of Molecular Genetics of the Czech Academy of Sciences, Videňská 1083, 142 20, Prague 4, Czech Republic
700    1_
$a Medvedíková, Martina $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic
700    1_
$a Matějková, Stanislava $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610, Prague 6, Czech Republic
700    1_
$a Lišková, Barbora $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic $7 xx0267204
700    1_
$a Gurská, Soňa $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic $7 xx0267298
700    1_
$a Džubák, Petr $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900, Olomouc, Czech Republic
700    1_
$a Brynda, Jiří $u Institute of Molecular Genetics of the Czech Academy of Sciences, Videňská 1083, 142 20, Prague 4, Czech Republic. Electronic address: brynda@img.cas.cz
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900, Olomouc, Czech Republic. Electronic address: marian.hajduch@upol.cz
700    1_
$a Grüner, Bohumír $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, 250 68, Řež, Czech Republic. Electronic address: gruner@iic.cas.cz
700    1_
$a Řezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610, Prague 6, Czech Republic. Electronic address: pavlina.rezacova@uochb.cas.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 200, č. - (2020), s. 112460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32505851 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20211209131410 $b ABA008
999    __
$a ok $b bmc $g 1650598 $s 1132639
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 200 $c - $d 112460 $e 20200518 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace